A Once-Daily Acne Pill Cut Lesions by More Than Seventy Percent

A once-daily oral Acne Pill cut total lesions by more than seventy percent across a full year of treatment in a late-stage clinical trial, according to results Sagimet Biosciences announced on October 9, 2026. The drug, denifanstat, is a first-in-class oral inhibitor of fatty acid synthase, an enzyme that drives sebum production, and the new data make it the furthest-advanced systemic Acne Pill with a novel mechanism in decades. The full 52 weeks of results will be presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas.

In the open-label extension trial, 57 percent of patients reached treatment success on the Investigator's Global Assessment scale, while total lesions fell 72 percent and inflammatory lesions dropped 77 percent from baseline. The drug was generally well tolerated across the year of dosing. The extension followed a 12-week randomized, double-blind, placebo-controlled parent trial, and 240 patients rolled over into the longer study, 116 of whom had received denifanstat from the start while 124 crossed over from placebo, as reported by Dermatology Times.

What makes the readout notable is the crossover detail. Patients who switched from placebo to denifanstat reached treatment success rates similar to those treated with the drug from the start, suggesting the benefit is tied to the medicine itself rather than to trial effects. Sagimet's chief medical officer Andreas Grauer said the results provide "meaningful long-term experience" with the 50 mg dose the company is carrying into its United States program.

How the Acne Pill works differently

Most acne treatments attack the condition from the outside in or suppress it indirectly. Topical retinoids and benzoyl peroxide work at the skin surface, oral antibiotics calm inflammation and bacteria but raise resistance concerns with long use, and isotretinoin, while powerful, carries a heavy side-effect and monitoring burden that keeps many patients away. Denifanstat takes a different route: by inhibiting fatty acid synthase, it dials down sebum production at the source, targeting one of the four core drivers of acne pathogenesis directly.

That mechanism is what the "first-in-class" label refers to. No approved oral acne therapy works this way, and the mechanistic data Sagimet is presenting alongside the clinical results are meant to support fatty acid synthase inhibition as a new therapeutic approach for the disease. For a condition where the newest systemic options are decades old, a genuinely new pathway matters more than another incremental formulation, according to the company's announcement.

The comparison that will follow the drug everywhere is isotretinoin, the current heavyweight for severe acne. Isotretinoin is highly effective but requires strict pregnancy-prevention programs, regular blood work, and management of dryness and mood-related warnings. An oral Acne Pill that works through sebum control without that apparatus would change the conversation for patients who cannot or will not take isotretinoin, though direct head-to-head data does not exist and the safety database for denifanstat is still growing.

What comes next for the Acne Pill

The timeline from here is already mapped. In China, where license partner Ascletis is developing the drug as ASC40, regulators accepted a new drug application in December 2025, putting a potential approval on the horizon there. In the United States, Sagimet's AURORA late-stage trial is now screening patients, with trial sites activated and institutional review board approvals in place, the company said.

AURORA is designed to enroll about 800 patients aged 12 and older, including roughly 450 adolescents, a population where moderate-to-severe acne is most common and where a once-daily pill could see its widest use. Screening began in October 2026, and the trial will test the same 50 mg daily dose that produced the year-long results, according to Managed Healthcare Executive. If the United States data mirror the China results, Sagimet would have a clear path toward a regulatory filing for the Acne Pill.

The counterpoints are real and worth stating plainly. The year-long data come from an open-label extension, which means every patient knew they were taking the drug, a design that can inflate apparent benefit compared with blinded trials. The parent trial was conducted entirely in China, so regulators and physicians elsewhere will want to see the results replicated in more diverse populations. And no version of the Acne Pill is approved anywhere yet; everything about its future depends on trials still enrolling.

Still, for the millions of teenagers and young adults cycling through antibiotics and topicals without lasting clearance, the emergence of a new oral mechanism is the most interesting acne story in years. Dermatology has waited a long time for a systemic option that is neither an antibiotic nor isotretinoin. Whether denifanstat becomes that option will be decided by the AURORA data, but the 52 weeks of results presented this week give the field its first serious look at what a sebum-targeting Acne Pill can do.

More health coverage is on the health topic page, including new research on genes that could predict hearing loss.